New diabetes drug retatrutide enters early human testing

NCT ID NCT06982859

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 1 study tests retatrutide, a new injectable drug, in 95 adults with type 2 diabetes who already take metformin. The goal is to see if retatrutide improves insulin sensitivity and beta-cell function better than placebo or semaglutide over 28 weeks. Participants will receive either retatrutide, semaglutide, or a placebo, and researchers will measure changes in how the body handles sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retatrutide (also known as LY3437943), an injectable drug
What this could lead to: If successful, retatrutide could offer a new treatment option for type 2 diabetes that improves how the body uses insulin and controls blood sugar.
What could go wrong: This is an early Phase 1 trial with only 95 participants, so results may not apply to everyone. The drug may cause side effects or not work better than existing treatments like semaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS INSULIN SENSITIVITY

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.